Friday, 16 Feb 2018

You are here

Upadacitinib Effective in Rheumatoid Arthritis

AbbVie released the preliminary results of a rheumatoid arthritis trial wherein its Jak inhibitor, upadacitinib, was tested against placebo, and shown to be superior in established RA patients who have failed prior DMARD therapy.

Two doses of upadacitinib (15 mg and 30 mg) were studied against placebo for 12 weeks and shown to produced significantly greater ACR20, ACR50, and  ACR70 scores (64%, 66%, 20%, respectively).

Clinical remission was seen in 31%, 28% and 10%, of those taking 15 mg, 30 mg and placebo (p<0.001). Low disease activity was achieved in 48% of patients on upadacitinib, compared to 17% of patients on placebo).

No new or surprising safety signals were reported.

Updacitinib is being considered for other indications, including psoriatic arthritis, Crohn's disease, ulcerative colitis and atopic dermatitis.

 

 

 

 

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Abatacept Improves GvHD Outcomes

The results from a phase 2 clinical trial presented at the American Society of Hematology meeting demonstrated that the drug abatacept was highly effective in managing severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

Biosimilar Reports - February 2018

Biosimilars command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need.  The global biosimilar market is expected to reach $36 billion USD by 2022. Here is this month's roundup of clinical trials and journal articles, overviews/reviews, practice and physician attitudes, and regulatory and pharma news - all on the subject of biosimilars.

Less Cardiovascular Risk with Abatacept in Rheumatoid Arthritis

A claims data analysis shows that abatacept use in rheumatoid arthritis (RA) patients yielded a modestly reduced cardiovascular risk when compared to patients receiving TNF inhibitors (TNFi).

FDA Approves Mepolizumab for Churg-Strauss (EGPA)

The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA. 

EGPA is rare with an stimated incidence of 0.11 to 2.66 cases per 1 million per year and an overall prevalence of 10.7 to 14 per 1,000,000 adults.

Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events?

Drug Safety has published a systematic review of the FDA’s Adverse Event Reporting System (FAERS) and finds numerous reports of thromboembolic adverse events (AEs) associated with two currently marketed Janus kinase (JAK) inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi). (Citation source: https://buff.ly/2zXyY2X)